Psychiatry and Neurology, Neurology · Bedford, TX
NPI
1558337238
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
4001 Airport Fwy Ste 130
Bedford, TX, 76021
Phone (817) 886-0369
Groups this clinician bills Medicare through
Medicare paid, 2024
$213K
14,548 services
Medicare patients, 2024
525
Average age 75
Drug cost, 2024
$1.7M
2,884 prescriptions
Company payments, 2025
$339
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Madhavi Thomas was code J0585 (injection, onabotulinumtoxina, 1 unit), 9,880 times for 20 patients. In total Madhavi Thomas billed 14,548 services in 25 codes, and Medicare paid $213K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 9,880 | 20 | $4.88 | $48K |
| 99214 Office E&M - Established | Office | 486 | 194 | $90.08 | $44K |
| 99233 Hospital E&M - Subsequent | Facility | 254 | 106 | $91.78 | $23K |
| 95983 Electrical Nerve Conductivity | Office | 145 | 53 | $35.79 | $5,190 |
| 99223 Hospital E&M - Initial | Facility | 139 | 134 | $133.10 | $19K |
| 99232 Hospital E&M - Subsequent | Facility | 109 | 64 | $60.75 | $6,622 |
| 99205 Office E&M - New | Office | 103 | 103 | $153.92 | $16K |
| 95970 Electrical Nerve Conductivity | Office | 65 | 42 | $13.55 | $881 |
| 95984 Electrical Nerve Conductivity | Office | 62 | 28 | $32.92 | $2,041 |
| 99222 Hospital E&M - Initial | Facility | 56 | 56 | $101.21 | $5,668 |
| 64616 Musculoskeletal | Office | 48 | 17 | $147.72 | $7,091 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 35 | 30 | $12.55 | $439 |
| 99213 Office E&M - Established | Office | 31 | 30 | $61.86 | $1,918 |
| 99214 Office E&M - Established | Facility | 26 | 23 | $74.78 | $1,944 |
| 99215 Office E&M - Established | Facility | 22 | 21 | $109.97 | $2,419 |
By year: 2022 $73K for 7,311 services; 2023 $120K for 10,193 services; 2024 $213K for 14,548 services.
Medicare prescription drug claims, 2024
In 2024, the drug Madhavi Thomas prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 622 prescriptions and refills. In total Madhavi Thomas wrote 2,884 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 622 | 1,243 | 182 | $19K |
| Rytary Carbidopa/Levodopa | 268 | 435 | 55 | $347K |
| Amantadine Amantadine Hcl | 169 | 290 | 41 | $7,462 |
| Clonazepam Generic | 151 | 157 | 39 | $907 |
| Neupro Rotigotine | 90 | 150 | 19 | $127K |
| Nuplazid Pimavanserin Tartrate | 82 | 109 | Under 11 | $519K |
| Escitalopram Oxalate Generic | 82 | 127 | 19 | $759 |
| Primidone Generic | 78 | 150 | 22 | $1,534 |
| Levetiracetam Generic | 76 | 149 | 29 | $1,877 |
| Rivastigmine Rivastigmine Tartrate | 70 | 106 | 16 | $4,077 |
| Quetiapine Fumarate Generic | 69 | 80 | 22 | $1,622 |
| Propranolol Hcl Generic | 65 | 89 | 22 | $819 |
| Gabapentin Generic | 63 | 114 | 25 | $908 |
| Zolpidem Tartrate Generic | 55 | 61 | Under 11 | $226 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 54 | 128 | 16 | $1,926 |
Brand drugs: 622 claims; generic drugs: 2,262 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Madhavi Thomas $339 ($339 in general payments such as food, travel and fees) from 8 companies. The largest payer was Abbott Laboratories with $90.18.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.